In the previous study, we showed that bone‐derived MSCs in combination with erythropoietin (EPO) can significantly reduce the newborn mice alveolar injury and lung fibrosis induced by high oxygen than MSCs therapy alone,2 but the transplant timing has not been reported. The gene discussed is EPO; the disease is pulmonary fibrosis.